<DOC>
	<DOCNO>NCT02728752</DOCNO>
	<brief_summary>Prospective , Double-blind , Randomized , Placebo-Controlled Phase III Study Evaluating Efficacy Safety Octagam 10 % Patients With Dermatomyositis ( `` ProDERM study '' )</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety Octagam 10 % Patients With Dermatomyositis ( Idiopathic Inflammatory Myopathy )</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Myositis</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>1 . Subjects diagnosis definite probable DM accord Bohan Peter criterion . 2 . Subjects treatment corticosteroid and/or maximally 2 immunesuppressants stable therapy least 4 week . 3 . Subjects active disease , assess agree upon independent adjudication committee . 4 . Manual Muscle Testing8 ( MMT8 ) score &lt; 142 , least 2 abnormal Core Set Measures ( CSM ) ( Visual Analogue Scale [ VAS ] patient global activity ≥2 cm , physician 's global disease activity ≥2 cm , extramuscular activity ≥2 cm ; least one muscle enzyme &gt; 1.5 time upper limit normal , Health Assessment Questionnaire ≥0.25 ) . 5 . Males females ≥ 18 &lt; 80 year age . 6 . Voluntarily give , fully inform write consent obtain subject studyrelated procedure conduct . 7 . Subject must capable understand comply relevant aspect study protocol . 1 . Cancerassociated myositis , define diagnosis myositis within 2 year diagnosis cancer ( except basal squamous cell skin cancer carcinoma situ cervix excise cure least 5 year pass since excision ) . 2 . Evidence active malignant disease malignancy diagnose within previous 5 year ( include hematological malignancy solid tumor ) breast cancer diagnose within previous 10 year . 3 . Subjects overlap myositis ( except overlap Sjögren 's syndrome ) , connective tissue disease associate DM , inclusion body myositis , polymyositis druginduced myopathy . 4 . Subjects immunemediated necrotizing myopathy absence typical DM rash . 5 . Subjects generalize , severe musculoskeletal condition DM prevent sufficient assessment subject physician . 6 . Subjects receive IgG treatment within last 6 month enrolment . 7 . Subjects receive blood plasmaderived product ( IgG ) plasma exchange within last 3 month enrolment . 8 . Subjects start plan start physical therapydirected exercise regimen trial . 9 . Cardiac insufficiency ( New York Heart Association III/IV ) , cardiomyopathy , significant cardiac dysrhythmia require treatment , unstable advanced ischemic heart disease . 10 . Severe liver disease , E.g . hepatitis cirrhosis . 11 . Severe kidney disease ( creatinine 1.5 time upper limit normal ) . 12 . Known hepatitis B , hepatitis C HIV infection . 13 . Subjects history deep vein thrombosis within last year prior study enrollment pulmonary embolism ever . 14 . Body mass index ≥40 kg/m2 . 15 . Medical condition whose symptom effect could alter protein catabolism and/or IgG utilization ( e.g . proteinlosing enteropathy , nephrotic syndrome ) . 16 . Known IgA deficiency antibody IgA . 17 . History hypersensitivity , anaphylaxis severe systemic response immunoglobulin , blood plasma derive product component Octagam 10 % . 18 . Known blood hyperviscosity , hypercoagulable state . 19 . Subjects history drug abuse within past 5 year prior study enrollment . 20 . Subjects unable unwilling understand comply study protocol . 21 . Participating another interventional clinical study investigational treatment within 3 month prior study enrollment . 22 . Women breast feeding , pregnant , plan become pregnant , unwilling apply effective birth control method study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>DM</keyword>
</DOC>